公开(公告)号：USRE47141E1

公开(公告)日：2018-11-27

申请号：US15382065

申请日：2016-12-16

Applicant: EWHA University—Industry Collaboration Foundation

Inventor： Dae-Kee Kim ,  Yhun Yhong Sheen ,  Chenghua Jin ,  Chul-Yong Park ,  Sreenu Domalapally ,  Sudhakar Rao Kota ,  Krishnaiah Maddeboina ,  Subrahmanyam Vura Bala

IPC: A61K31/437 ,  C07D471/04 ,  A61K31/5377

Abstract: This invention relates to use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.

公开(公告)号：USRE47122E1

公开(公告)日：2018-11-13

申请号：US15382135

申请日：2016-12-16

Applicant: EWHA University—Industry Collaboration Foundation

Inventor： Dae-Kee Kim ,  Yhun Yhong Sheen ,  Chenghua Jin ,  Chul-Yong Park ,  Sreenu Domalapally ,  Sudhakar Rao Kota ,  Krishnaiah Maddeboina ,  Subrahmanyam Vura Bala

IPC: A61K31/44 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.